Oluwanifemi Ajayi

Oluwanifemi Ajayi

Auto-generated profile, based on publicly available information

Oluwanifemi Ajayi

Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ilishan-Remo 121109, Ogun State, Nigeria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2024 in Avicenna Journal of Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Yomi Akele
Richard Yomi Akele
AOAdesuyi Ayodeji Omoare
Adesuyi Ayodeji Omoare
BDBanenat Dogonyaro
Banenat Dogonyaro
MIMichael Unata Iduh
Michael Unata Iduh
TATemitayo Oluwatomisin Ajayi
Temitayo Oluwatomisin Ajayi
Mpox, declared a Public Health Emergency of International Concern by the World Health Organization (WHO), poses a growing global threat. The resurgence, driven by the highly transmissible and severe clade Ib strain from the Democratic Republic of the Congo, raises concerns about a potential pandemic. This narrative review aims to identify actionable strategies to mitigate the current Mpox outbreak by leveraging lessons from past health crises, particularly COVID-19, and to highlight future research priorities essential for global preparedness. A comprehensive literature review from 2018 to 2024 was conducted using Google Scholar, Scopus, and PubMed databases, focusing on Mpox transmission, vaccine efficacy, antiviral treatments, and public health responses. Our findings revealed that the resurgence of Mpox is fueled by viral evolution, ecological changes, and inadequate surveillance, exacerbated by inequitable healthcare access and insufficient public health infrastructure. While existing vaccines, such as Jynneos and ACAM2000, offer protection, their long-term efficacy and safety across diverse populations require further study. Antiviral treatments, including tecovirimat and brincidofovir, show promise but lack optimized care protocols and face challenges such as emerging resistance. Lessons from the COVID-19 response underscore the importance of enhancing global surveillance systems, strengthening healthcare infrastructure, ensuring equitable vaccine distribution, and fostering community engagement. Effective Mpox management also requires standardized treatment guidelines and the integration of genomic monitoring to track viral evolution and drug resistance. Urgent international collaboration is needed to avert a potential Mpox pandemic. Priorities include advancing research on long-term vaccine efficacy, optimizing antiviral therapies, and improving care for severe cases. Actionable recommendations include robust policies, sustainable funding, and global collaboration to strengthen pandemic preparedness and mitigate Mpox’s impact.

24 October 2024 in Acta Elit Salutis
Verified
Journal Article
Open access
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Akele
Richard Akele
KAKhairah Adedotun
Khairah Adedotun
MIMichael Iduh
Michael Iduh
EOErnest Ohanu
Ernest Ohanu
OAOluwanifemi Ajayi
Oluwanifemi Ajayi
Background: Dengue fever remains a global health threat, particularly in tropical regions, with no effective vaccines or antiviral treatments available. This review explores plant-based therapies as a promising approach to manage dengue by focusing on bioactive compounds, immunotargets, and mechanisms of action. Aim: The review aims to explore the therapeutic potential of phytomedicines in dengue management, highlighting their antiviral and immune-modulating effects, and addressing the challenges in clinical application. Methods: In this review, a comprehensive literature search was conducted, sourcing peer-reviewed articles on medicinal plants and their bioactive compounds in relation to dengue fever. The review analyzes the interaction of these compounds with key immunotargets and their mechanisms in alleviating dengue symptoms. Results: Plants such as Andrographis paniculata, Azadirachta indica, Carica papaya, Curcuma longa, Tinospora cordifolia, and Euphorbia hirta contain bioactive compounds like flavonoids, alkaloids, terpenoids, and saponins. These compounds inhibit viral replication, modulate immune responses, and target critical immunotargets, including viral proteins and cytokine production. For example, quercetin suppresses viral replication, while berberine reduces pro-inflammatory cytokines, potentially reducing dengue complications. Terpenoids, with their anti-inflammatory properties, can mitigate excessive immune activation. Saponins may enhance antiviral defenses, lowering viral load and disease severity. Conclusion: Phytomedicines offer significant potential as adjunct therapies for dengue, with antiviral and immune-modulating properties. However, challenges related to standardization, quality control, and variability in active compound concentrations must be addressed to ensure their clinical application. Integrating phytomedicines with conventional therapies may provide effective and sustainable strategies for managing dengue globally.

17 March 2026 in Jordan Medical Journal
Verified
Journal Article
Closed access
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Akele
Richard Akele
OOOsareniro Osakue
Osareniro Osakue
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
CIChinwendu Ikonne
Chinwendu Ikonne
OAOluwanifemi Ajayi
Oluwanifemi Ajayi
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the progressive destruction of pancreatic beta cells. Coxsackie B Virus (CVB), particularly CVB1, CVB3, and CVB4, has been identified as a key environmental trigger in the pathogenesis of T1DM, particularly in genetically predisposed individuals. This narrative review synthesizes two decades of evidence (2005–2025) to explore the mechanisms by which CVB contributes to autoimmunity and emerging prevention strategies. CVB induces beta cell autoimmunity through molecular mimicry, bystander activation, and persistent viral infections that promote chronic inflammation and immune-mediated beta cell damage. Specific serotypes, such as CVB3 and CVB4, have been shown to have stronger associations with T1DM onset, emphasizing the importance of targeted interventions for these serotypes. Recent advancements in prevention strategies include multivalent CVB vaccines, antiviral agents such as pleconaril, and immune-modulating therapies like tolerogenic vaccines and regulatory T cell (Treg) expansion. However, challenges remain regarding their safety, timing of administration, and immune cross-reactivity. Early diagnostic efforts focused on biomarkers such as CVB-specific antibodies, islet autoantibodies (e.g., GAD65, ICA, ZnT8), and HLA risk alleles are crucial for identifying individuals in the latent phase of T1DM. To mitigate the risk of CVB-induced T1DM, an integrated public health approach—combining virological surveillance, vaccination campaigns, and early immunological screening—is essential. We recommend prioritizing longitudinal cohort studies, the development of safe multivalent vaccines, and investment in community-based early detection programs. A collaborative, multidisciplinary approach is vital to prevent or delay T1DM onset in at-risk populations